Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2′,3′-dideoxy-5-fluoro-3′-thiacytidine [FTC]), and tenofovir alafenamide (Taf) has been recently approved by the European Medicines Agency for the treatment of HIV infection, and is the first ever protease-inhi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug Des Devel Ther
Hauptverfasser: Squillace, Nicola, Bozzi, Giorgio, Colella, Elisa, Gori, Andrea, Bandera, Alessandra
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2018
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6211373/
https://ncbi.nlm.nih.gov/pubmed/30464395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S147493
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge